A Phase 2 interventional study of CHIKV VLP/unadjuvanted and CHIKV VLP/adjuvanted in Chikungunya Virus Infection, sponsored by Bavarian Nordic. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Bavarian Nordic · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Chikungunya Fever with a site in United States — 1 open to participants now, 4 under way, 3 of them phase 3. Chikungunya Fever · United States.
Among the 18 studies in Chikungunya Fever with a site in United States, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 5th registered.
88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.
Browse Chikungunya Fever studies →1 of the 18 studies in Chikungunya Fever with a site in United States is open now. Recruiting first, the newest first:
Cepheid · Sites in United States
Ages 14+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2018.
This study's enrollment of 445 is above the median of 263 across 57 interventional studies indexed under Chikungunya Fever.
Median enrollment 272 across the 16 interventional studies, 1,267 across the 2 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
Bavarian Nordic is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.
Bavarian Nordic has 7 studies filed under Chikungunya Fever — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Chikungunya Fever with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.
Primary Objective:
To assess the immune response to the vaccine
Secondary Objectives:
To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine
Safety Objective:
To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine
The trial will explore 8 formulation/schedule combinations of CHIKV VLP vaccine with or without Alhydrogel adjuvant, and will also explore different dose schedules of Day 1 and 15 or Day 1 and 29 or Day 29 only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
Biological: CHIKV VLP/unadjuvanted · Biological: Placebo
6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
Biological: CHIKV VLP/adjuvanted · Biological: Placebo
20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
Biological: CHIKV VLP/adjuvanted
40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
Biological: CHIKV VLP/adjuvanted
Vaccine consists of virus-like particles of chikungunya virus antigens
Adjuvanted formulation includes Alhydrogel
Placebo is vaccine diluent alone
Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.
To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.
Time frame: Day 57 (from Day 1 vaccination), 28 days after the last injection.
Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.
To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.
Time frame: At Days 8, 15, 22, 29, 36, and 57.
Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.
To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.
Time frame: At Days 182, 365, 547, and 760.
Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.
To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.
Time frame: Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.
Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.
Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.
Time frame: Day 57 (from Day 1 vaccination), 28 days after the last injection.
Participants were recruited at 3 U.S. sites.
| Milestone | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 53 | 52 | 51 | 50 | 53 | 53 | 51 | 52 | 20 | 10 |
| Exposed / safety | 53 | 52 | 50 | 51 | 53 | 53 | 51 | 52 | 20 | 10 |
| Immunogenicity-evaluable | 47 | 44 | 44 | 45 | 48 | 48 | 47 | 50 | 20 | 10 |
| Completed | 42 | 42 | 39 | 41 | 43 | 47 | 46 | 39 | 18 | 10 |
| Not completed | 11 | 10 | 12 | 9 | 10 | 6 | 5 | 13 | 2 | 0 |
| Withdrew: Lost to follow-up | 7 | 6 | 6 | 6 | 6 | 4 | 4 | 11 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 5 | 3 | 4 | 2 | 1 | 2 | 1 | 0 |
| Withdrew: Other than ae, death, pi decision, ltfu, noncompliance, study terminated, or withdrawal of consent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.
| titer | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) |
|---|---|---|---|---|---|---|---|---|
| Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8. | 2057.0 (1584.8 to 2670.0) | 1116.2 (852.5 to 1461.4) | 1465.3 (1119.1 to 1918.4) | 2023.8 (1550.5 to 2641.7) | 920.1 (710.9 to 1190.9) | 1206.9 (932.4 to 1562.2) | 1562.8 (1204.1 to 2028.3) | 1712.5 (1330.0 to 2205.0) |
To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.
| titer | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) |
|---|---|---|---|---|---|---|---|---|
| Day 8 | 70.6 (53.2 to 93.7) | 34.3 (25.6 to 46.1) | 72.6 (54.2 to 97.2) | 117.6 (87.8 to 157.4) | 8.4 (6.3 to 11.1) | 7.5 (5.7 to 10.0) | 7.5 (5.7 to 10.0) | 7.5 (5.7 to 9.9) |
| Day 15 | 419.3 (323.6 to 543.4) | 189.4 (144.9 to 247.6) | 530.2 (405.6 to 693.0) | 912.7 (700.4 to 1189.5) | 7.7 (6.0 to 10.0) | 7.5 (5.8 to 9.7) | 7.7 (5.9 to 9.9) | 7.5 (5.8 to 9.6) |
| Day 22 | 691.5 (499.2 to 957.9) | 351.3 (250.9 to 492.0) | 1400.2 (999.9 to 1960.8) | 2198.1 (1575.6 to 3066.5) | 46.4 (33.6 to 64.1) | 63.1 (45.7 to 87.1) | 119.0 (85.9 to 164.9) | 7.5 (5.5 to 10.3) |
| Day 29 | 417.2 (305.4 to 570.0) | 277.3 (200.9 to 382.8) | 890.5 (645.1 to 1229.2) | 1238.1 (900.2 to 1702.9) | 258.0 (189.5 to 351.3) | 328.8 (241.5 to 447.6) | 886.2 (648.7 to 1210.5) | 8.2 (6.0 to 11.0) |
| Day 36 | 3442.8 (2533.9 to 4677.8) | 1675.8 (1220.9 to 2300.2) | 2772.4 (2019.8 to 3805.4) | 3435.0 (2511.4 to 4698.1) | 1327.7 (980.4 to 1797.9) | 2155.4 (1591.6 to 2919.0) | 3609.0 (2647.7 to 4919.3) | 157.9 (117.3 to 212.6) |
| Day 57 | 2057.0 (1584.8 to 2670.0) | 1116.2 (852.5 to 1461.4) | 1465.3 (1119.1 to 1918.4) | 2023.8 (1550.5 to 2641.7) | 920.1 (710.9 to 1190.9) | 1206.9 (932.4 to 1562.2) | 1562.8 (1204.1 to 2028.3) | 1712.5 (1330.0 to 2205.0) |
To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.
| titer | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) |
|---|---|---|---|---|---|---|---|---|
| Day 182 | 345.1 (258.1 to 461.3) | 209.0 (153.1 to 285.2) | 358.4 (261.6 to 491.2) | 486.6 (360.5 to 656.9) | 253.4 (188.4 to 340.9) | 303 (226.7 to 405.0) | 388.1 (291.3 to 517.1) | 505.7 (380.7 to 671.8) |
| Day 365 | 243.4 (176.8 to 334.9) | 137.5 (98.3 to 192.3) | 226.7 (160.6 to 320.0) | 336.6 (244.6 to 463.2) | 195.2 (141.3 to 269.6) | 246.9 (180.1 to 338.4) | 302.0 (220.3 to 414.0) | 491.7 (362.5 to 667.0) |
| Day 547 | 169.2 (126.2 to 226.8) | NA (NA to NA) | NA (NA to NA) | 215.7 (160.9 to 289.1) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 297.9 (221.4 to 400.8) |
| Day 760 | 169.8 (122.4 to 235.5) | NA (NA to NA) | NA (NA to NA) | 5365.1 (3853.2 to 7470.1) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 279.7 (200.1 to 391.1) |
To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.
| titer | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) |
|---|---|
| Day 547 (pre-boost) | 223.6 (166.7 to 299.9) |
| Day 575 (post-boost) | 12325.8 (8951.4 to 16972.4) |
| Day 760 (post-boost) | 5874.2 (4269.4 to 8082.3) |
Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.
| Participants | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) |
|---|---|---|---|---|---|---|---|---|
| Titer at or above 15 | 47 | 44 | 44 | 45 | 48 | 48 | 47 | 50 |
| Titer at or above 40 | 47 | 44 | 43 | 45 | 48 | 48 | 47 | 50 |
| Titer at or above 160 | 47 | 42 | 43 | 45 | 47 | 48 | 46 | 50 |
| Titer at or above 640 | 43 | 32 | 41 | 43 | 29 | 40 | 41 | 44 |
| Titer at or above 4-fold rise over baseline | 47 | 44 | 43 | 45 | 48 | 48 | 47 | 50 |
Collected over Unsolicited adverse events were monitored through Day 760 (Groups 1, 4, and 8), Day 365 (Groups 2, 3, 5, 6, and 7), Day 182 (Group 9), and Day 29 (Group 10), but only unsolicited adverse events occurring through Day 57 (end of treatment and observation period, 28 days after last dose for Groups 1-8) are reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | 0/53 (0%) | 0/53 (0%) | 26/53 (49.1%) |
| Group 2: 6 mcg/Adjuvant (Day 1 & 29) | 0/52 (0%) | 1/52 (1.9%) | 35/52 (67.3%) |
| Group 3: 10 mcg/Adjuvant (Day 1 & 29) | 0/50 (0%) | 2/50 (4%) | 36/50 (72%) |
| Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | 0/51 (0%) | 1/51 (2%) | 34/51 (66.7%) |
| Group 5: 6 mcg/Adjuvant (Day 15 & 29) | 0/53 (0%) | 0/53 (0%) | 29/53 (54.7%) |
| Group 6: 10 mcg/Adjuvant (Day 15 & 29) | 0/53 (0%) | 0/53 (0%) | 28/53 (52.8%) |
| Group 7: 20 mcg/Adjuvant (Day 15 & 29) | 0/51 (0%) | 2/51 (3.9%) | 30/51 (58.8%) |
| Group 8: 40 mcg/Adjuvant (Day 29) | 0/52 (0%) | 3/52 (5.8%) | 34/52 (65.4%) |
| Group 9: 20 mcg/Adjuvant (Day 1 & 29) | 0/20 (0%) | 0/20 (0%) | 12/20 (60%) |
| Group 10: 40 mcg/Adjuvant (Day 1) | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/53 | 0/52 | 1/50 | 0/51 | 0/53 | 0/53 | 0/51 | 0/52 | 0/20 | 0/10 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/53 | 0/52 | 1/50 | 0/51 | 0/53 | 0/53 | 0/51 | 0/52 | 0/20 | 0/10 |
| GastroenteritisInfections and infestations | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 1/51 | 0/52 | 0/20 | 0/10 |
| Laryngeal injuryInjury, poisoning and procedural complications | 0/53 | 0/52 | 0/50 | 1/51 | 0/53 | 0/53 | 0/51 | 0/52 | 0/20 | 0/10 |
| Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 1/51 | 0/52 | 0/20 | 0/10 |
| Premature separation of placentaPregnancy, puerperium and perinatal conditions | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 1/51 | 0/52 | 0/20 | 0/10 |
| Threatened labourPregnancy, puerperium and perinatal conditions | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 1/51 | 0/52 | 0/20 | 0/10 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 1/51 | 0/52 | 0/20 | 0/10 |
| Biliary dyskinesiaHepatobiliary disorders | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 0/51 | 1/52 | 0/20 | 0/10 |
| AppendicitisInfections and infestations | 0/53 | 0/52 | 0/50 | 0/51 | 0/53 | 0/53 | 0/51 | 1/52 | 0/20 | 0/10 |
| Event | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain, solicitedGeneral disorders | 19/53 | 27/52 | 23/50 | 29/51 | 18/53 | 18/53 | 18/51 | 26/52 | 10/20 | 2/10 |
| Myalgia, solicitedMusculoskeletal and connective tissue disorders | 11/53 | 12/52 | 12/50 | 21/51 | 11/53 | 10/53 | 11/51 | 11/52 | 0/20 | 2/10 |
| Headache, solicitedNervous system disorders | 11/53 | 14/52 | 18/50 | 20/51 | 11/53 | 11/53 | 14/51 | 19/52 | 3/20 | 1/10 |
| Fatigue, solicitedGeneral disorders | 11/53 | 12/52 | 12/50 | 19/51 | 7/53 | 7/53 | 11/51 | 10/52 | 2/20 | 2/10 |
| Nausea, solicitedGastrointestinal disorders | 8/53 | 6/52 | 8/50 | 14/51 | 4/53 | 5/53 | 6/51 | 6/52 | 1/20 | 0/10 |
| Malaise, solicitedGeneral disorders | 7/53 | 7/52 | 6/50 | 14/51 | 4/53 | 7/53 | 10/51 | 9/52 | 2/20 | 1/10 |
| Arthralgia, solicitedMusculoskeletal and connective tissue disorders | 3/53 | 9/52 | 4/50 | 12/51 | 3/53 | 4/53 | 4/51 | 6/52 | 1/20 | 1/10 |
| Chills, solicitedGeneral disorders | 1/53 | 3/52 | 5/50 | 8/51 | 3/53 | 4/53 | 4/51 | 3/52 | 0/20 | 0/10 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/53 | 0/52 | 0/50 | 2/51 | 0/53 | 0/53 | 0/51 | 0/52 | 0/20 | 1/10 |
| GastroenteritisInfections and infestations | 0/53 | 1/52 | 1/50 | 0/51 | 0/53 | 0/53 | 4/51 | 1/52 | 0/20 | 0/10 |
Randomized participants.
| Age, Categorical(Participants) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| Between 18 and 65 years | 50 | 51 | 51 | 50 | 53 | 52 | 51 | 52 | 20 | 10 | 440 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 30.4 ± 8.22 | 31.2 ± 8.26 | 31.2 ± 7.64 | 33.7 ± 7.53 | 30.6 ± 7.72 | 32.9 ± 7.53 | 32.4 ± 7.78 | 31.6 ± 7.82 | 27.1 ± 7.58 | 29.6 ± 7.65 | 31.5 ± 7.86 |
| Sex: Female, Male(Participants) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 30 | 30 | 37 | 32 | 38 | 29 | 27 | 26 | 7 | 3 | 259 |
| Male | 23 | 22 | 14 | 18 | 15 | 24 | 24 | 26 | 13 | 7 | 186 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 4 | 3 | 4 | 8 | 2 | 4 | 2 | 1 | 35 |
| Not Hispanic or Latino | 50 | 48 | 47 | 47 | 49 | 45 | 49 | 48 | 18 | 9 | 410 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Asian | 0 | 2 | 1 | 2 | 0 | 1 | 0 | 2 | 1 | 0 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Black or African American | 10 | 9 | 14 | 13 | 14 | 9 | 15 | 7 | 7 | 6 | 104 |
| White | 43 | 40 | 36 | 35 | 36 | 40 | 34 | 41 | 11 | 4 | 320 |
| More than one race | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 2 | 0 | 0 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 53 | 52 | 51 | 50 | 53 | 53 | 51 | 52 | 20 | 10 | 445 |
| Day 1 predose (baseline) geometric mean anti-chikungunya luciferase neutralizing antibody titer.(titer) | Group 1: 20 mcg/Unadjuvant (Day 1 & 29) | Group 2: 6 mcg/Adjuvant (Day 1 & 29) | Group 3: 10 mcg/Adjuvant (Day 1 & 29) | Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) | Group 5: 6 mcg/Adjuvant (Day 15 & 29) | Group 6: 10 mcg/Adjuvant (Day 15 & 29) | Group 7: 20 mcg/Adjuvant (Day 15 & 29) | Group 8: 40 mcg/Adjuvant (Day 29) | Group 9: 20 mcg/Adjuvant (Day 1 & 29) | Group 10: 40 mcg/Adjuvant (Day 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Geometric mean | 7.5 (7.5 to 7.5) | 7.5 (7.5 to 7.5) | 7.5 (7.5 to 7.5) | 7.5 (7.5 to 7.5) | 7.8 (7.5 to 50.3) | 7.5 (7.5 to 7.5) | 7.5 (7.5 to 7.5) | 7.5 (7.5 to 7.5) | 8.6 (7.5 to 117.1) | 9.0 (7.5 to 46.1) | 7.6 (7.5 to 117.1) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Sep 2020, 28 months.
Results were first posted in Nov 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.